Mette S. van Ramshorst

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 144 citations · Full text

Medicine, Oncology, Breast Oncology +15

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

Tessa G. Steenbruggen, Erik van Werkhoven, Mette S. van Ramshorst et al. · European Journal of Cancer · 2020 · 118 citations · Full text

Medicine, Oncology, Breast Oncology +10

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy

Mette S. van Ramshorst, Claudette E. Loo, Emilie J. Groen et al. · Breast Cancer Research and Treatment · 2017 · 43 citations

Medicine, Oncology, Radiology +16

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 43 citations · Full text

Medicine, Oncology, Radiology +14